[go: up one dir, main page]

WO2018080039A1 - Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune - Google Patents

Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune Download PDF

Info

Publication number
WO2018080039A1
WO2018080039A1 PCT/KR2017/010817 KR2017010817W WO2018080039A1 WO 2018080039 A1 WO2018080039 A1 WO 2018080039A1 KR 2017010817 W KR2017010817 W KR 2017010817W WO 2018080039 A1 WO2018080039 A1 WO 2018080039A1
Authority
WO
WIPO (PCT)
Prior art keywords
stage
leaves
leaf extract
extract
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/010817
Other languages
English (en)
Korean (ko)
Inventor
김수나
강영규
신승현
이용희
나용주
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorepacific Corp
Original Assignee
Amorepacific Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorepacific Corp filed Critical Amorepacific Corp
Publication of WO2018080039A1 publication Critical patent/WO2018080039A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/045—Organic compounds containing nitrogen as heteroatom
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q7/00—Preparations for affecting hair growth
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/20—Natural extracts
    • A23V2250/21—Plant extracts

Definitions

  • the present invention relates to a composition for preventing hair loss or hair growth containing maple leaf extract, and more specifically, by containing an extract extracted from soybean leaves in which the color of the bean leaf has changed yellow during the growth of soybean. It relates to a composition.
  • the scalp is composed of epidermis, dermis and subcutaneous tissue.
  • the outermost epidermis functions to protect sensitive tissues of the body from damage.
  • environmental factors affecting the scalp such as changes in temperature, humidity, and stress and lack of influence due to external stimuli such as exposure to pollutants, can lead to loss of scalp function and affect hair loss. .
  • Tissues associated with hair loss include sebaceous gland, keratinocytes of the epidermis and hair follicles, dermal papilla cells (dermal papilla cells), sweat gland, and root sheath of the scalp hair. foll icle).
  • DHT dihydrotestosterone
  • Androgenetic alopecia is caused by a male hormone called testosterone, which is converted into a more powerful hormone, dihydrotestosterone, by an enzyme called 5-alpha reductase (5 alpha-reductase). It acts on the hair follicles and induces hair follicles from the growth stage to the degenerative stage and causes hair loss. Therefore, a method of inhibiting the production of DHT by 5 alpha-reductase is mainly used to treat androgenetic alopecia.
  • the 5-alpha reductase inhibitor finasteride has been shown to improve hair loss by reducing the hair loss hormone DHT in alopecia patients (Van Neste et al. , 2000) .
  • DHT hair loss hormone
  • Gynecologic alopecia is mainly caused by a decrease in the amount of estrogen after menopause.
  • Minoxidil or estrogen is mainly used as a treatment for female alopecia.
  • Alopecia areata is caused by autoimmune diseases, mental stress, or genetic predisposition. This alopecia areata is fundamentally different from androgenetic alopecia, and the treatment is also different, using a method of treating corticosteroids, or applying minoxidil to the affected area or artificially causing irritation in the affected area.
  • ingredients for the purpose of promoting blood circulation, inhibiting the action of testosterone, and strengthening the hair root function, etc. are sold as products on the market, but there are still no clear effects and problems of side effects. May be raised.
  • minoxidil has been reported to cause sticky feeling and irritation to the skin.
  • Finasteride is currently used as an oral preparation, but side effects such as sexual dysfunction have been reported according to its intake. The effect can be expected only by oral administration, there was a lot of inconvenience in use.
  • hormone replacement therapy is used as the most effective method.
  • hormones such as estrogen
  • carcinogenesis such as breast cancer and uterine cancer
  • problems such as side effects such as headache and weight gain.
  • isoflavone of soybean an phytoestrogen extracted from plants
  • is commonly used for hair loss improvement but issues regarding effects and safety have been continuously raised. Therefore, there is an urgent need for the development of a hair loss treatment agent using a safer and more effective natural derived material.
  • SERMs selective estrogen receptor modulators
  • SERMs selective estrogen receptor modulators, which are substances that bind to estrogen receptors and act as estrogen agonists in some tissues and as estrogen antagonists in other tissues.
  • Apigenin is a plant polyphenol that is widely distributed in fruits and vegetables, especially in parsley, celery, garlic and cabbage, and is known to have anti-inflammatory, anti-cancer and free radical scavenging properties. Kim et al., Prostag . Leukotr . Ess . , 58: 17-24, 1998).
  • Coumestrol is known to be extremely trace or rarely present in soy or legumes. Compared to isoflavones, cumestrol's estrogen activity is 30 to 100 times higher, which is very useful in relieving uterine cancer, bone marrow cancer, breast cancer or brain cancer and menopausal symptoms.
  • Caffeine stimulates the metabolism of dermal papilla cells to promote hair follicle growth (Kren et al, Zygote, 12 (1): 31-38, 2004; Tsianakas A et al., Arch. Dermatol . Res., 296: 450 , 2005), which has been reported to inhibit the action of dihydrotestosterone, an active male hormone that shrinks hair follicles (Fischer et al., Int J Dermatol. , 46 (1): 27-35, 2007). However, too much caffeine may affect the dermal papilla cells and cause cell death (Hashimoto et al., Cancer Res. , 64 (9): 3344-3349, 2004). There is also research.
  • Ginseng ( ⁇ , Panax ginseng CA Mey. 1909) is a perennial herb that belongs to the arboraceae family and is used as a medicinal herb.
  • the efficacy of ginseng on the active ingredient began to be revealed by Brekhman (1957) as a study on ginsenosides or saponins. Ginsenosides are known to have many effects such as cancer cell proliferation inhibitory effect, hypertension improvement, antioxidant effect, antistress and the like.
  • Green tea has been a perennial evergreen plant (eg Camellia sinensis ) belonging to the tea tree family, and has been drinking since the Three Kingdoms period.In recent years, its value has been recognised as the functionalities of green tea are gradually revealed. have.
  • Green tea contains high amounts of useful ingredients such as polyphenols (eg catechins), caffeine, amino acids, and vitamin C. It has been shown to be excellent for hangover and nicotine detoxification, fatigue recovery, cardiovascular action and skin beauty. Antioxidant action, anti-cholesterol action, hypoglycemic action, anti-tumor action, and platelet aggregation inhibitory effects on polyphenols, which are contained the most, have been attracting much attention.
  • Catechin the main physiologically active substance of green tea, is a polyphenol containing about 100 mg in a cup of green tea, mainly epigallocatechin gallate (hereinafter referred to as "EGCG”) and epicatechin gallate (epicatechin gallate).
  • EGCG epigallocatechin gallate
  • GC epicatechin gallate
  • EC epigallocatechin
  • ECC epigallocatechin
  • catechins are food materials having various bioregulatory functions such as anti-caries, antibacterial, antioxidant, deodorant action, blood glucose level and blood cholesterol elevation suppression, anti-tumor, and lipid peroxide production inhibitory action.
  • these catechins are known to have three to four times the antioxidant effect of vitamin C and vitamin E.
  • catechins are water-soluble, but tea leaves also contain fat-soluble components such as vitamin E and ⁇ -carotene. These components are used to remove free radicals and active oxygen-derived products that adversely affect immune response or cancer in vivo. It is known to be involved, and at the same time, it can be expected that synergistic effects can be expected when ingested with catechins, which also have antioxidant activity.
  • Wnt / ⁇ -catenin signaling system promotes hair follicle formation (Andl T, et al ., Dev Cell, 2 (5): 643-653, 2002) and maintains and activates genes that are expressed during the growth phase of the hair cycle. Plays an important role (Kishimoto J, et al., Genes & Dev , 14: 1181-1185, 2000) and promotes the differentiation of stem cells from keratinocytes (Huelsken J, et al., Cell 105 (4) : 533-545, 2001).
  • the activity of the Wnt / ⁇ -catenin signaling system is known to act on skin production and hair follicle development, and hair growth is inhibited in mice knocked down the Wnt gene.
  • substances that promote the activation of the Wnt / ⁇ -catenin signaling system present in hair follicle stem cells can promote hair growth.
  • Minoxidil is one of the hair growth promoting drugs approved by the US Food and Drug Administration (FDA) .It was originally developed as a vasodilator for the treatment of hypertension. It is becoming. The specific mechanism of the minoxidil's hair growth effect is not yet clear, but K ATP -channel opening, increased nutrient supply through vasodilation and activation of ⁇ -catenin pathway in human dermal papilla cells The back is thought to induce hair growth.
  • Human dermal papilla cells are mesoderm-derived fibroblasts, which produce hair cycles through the secretion of proteins such as insulin-like growth factor-1 (IGF-1), hepatocyte growth factor (HGF), and fibroblast growth factor-7 (FGF-7). Minoxidil is known to have an effect of proliferating the growth of human dermal papilla cells through lowering of apoptosis of human dermal papilla cells.
  • IGF-1 insulin-like growth factor-1
  • HGF hepatocyte growth factor
  • measuring the effects of inhibiting 5-alpha reductase activity, NIH3T3 fibroblast proliferation, and growth proliferation of human dermal papilla cells of any substance will help to effectively treat hair loss and improve hair growth. It can be a valid indicator to assess whether it can.
  • Patent Document 1 discloses the skin inflammation, allergy and atopic improvement effect and skin moisturizing effect of the composition comprising a soybean leaf extract
  • Patent Document 2 contains a composition containing a ginseng extract and green tea extract Efficacy of inhibiting hair loss, hair loss and dandruff of the invention is disclosed, but containing the extract extracted from the soybean leaves (ie, maple soybean) that the color of the soybean leaves turned yellow during the growth of the beans as an active ingredient, the composition for promoting hair growth and improving hair loss symptoms Is not disclosed.
  • the present inventors have developed a composition showing the effect of promoting hair growth and improving hair loss by containing an extract extracted from the soybean leaf extract, ie, the soybean leaf whose color has changed yellow during soybean growth. It was.
  • Patent Document 1 Korean Unexamined Patent Publication No. 10-2014-0034964 (2014.03.21.)
  • Patent Document 2 Korean Unexamined Patent Publication No. 10-2015-0030095 (2015.03.19.)
  • the present inventors have made diligent efforts to develop a composition containing a plant-derived SERM (phytoSERM) effective for preventing hair loss or improving hair growth, and thus extracted from a bean leaf (ie, maple leaf) in which the color of the bean leaf has changed yellow during the growth of the bean. It was confirmed that the extract exhibits the effect of promoting hair growth and improving hair loss symptoms by promoting the activity of the Wnt / ⁇ -catenin signaling system of dermal papilla cells, thereby completing the present invention.
  • a plant-derived SERM a plant-derived SERM
  • the main purpose of the present invention is to provide a composition containing as an active ingredient maple leaf extract excellent in promoting hair growth and preventing hair loss.
  • Another object of the present invention is a composition excellent in promoting hair growth and preventing hair loss, comprising mixing at least one substance selected from the group consisting of apigenin, cumestrol, caffeine, ginseng extract and green tea extract with maple leaf extract It is to provide a composition containing a mixture as an active ingredient.
  • the present invention is a composition for preventing hair loss or hair growth containing maple leaf extract as an active ingredient, preferably a pharmaceutical composition for hair loss prevention or hair growth containing maple leaf extract as an active ingredient, health function
  • a pharmaceutical composition for hair loss prevention or hair growth containing maple leaf extract as an active ingredient preferably a pharmaceutical composition for hair loss prevention or hair growth containing maple leaf extract as an active ingredient, health function
  • food compositions and cosmetic compositions are provided.
  • the present invention also prevents hair loss or improves hair growth, which contains a mixture of at least one substance selected from the group consisting of apigenin, cumestrol, caffeine, ginseng extract, and green tea extract as an active ingredient. It provides a composition for preventing hair loss or improving hair growth, preferably a nutraceutical composition and cosmetic composition containing the mixture as an active ingredient.
  • the present invention also provides the use of maple leaf extract as a hair loss preventing or hair growth improving agent in the manufacture of a pharmaceutical composition or medicine for preventing hair loss or hair growth.
  • the present invention also, in the manufacture of a pharmaceutical composition or medicament for preventing hair loss or hair growth, at least any one selected from the group consisting of apigenin, cumestrol, caffeine, ginseng extract and green tea extract and maple leaf It provides a use of the mixture of the extract as a hair loss preventing agent or hair growth improving agent.
  • the present invention also provides a use of maple leaf extract as a hair loss preventing agent or hair growth improving agent in the manufacture of a health food composition for preventing hair loss or hair growth.
  • the present invention also, in the production of a health food composition for preventing hair loss or hair growth, apigenin, cumestrol, caffeine, ginseng extract and green tea extract and at least one selected from the group consisting of maple leaf extract It provides a use of the mixture of the mixture as a hair loss preventing agent or hair growth improving agent.
  • the present invention also provides the use of maple leaf extract as a hair loss preventing agent or hair growth improving agent in the production of a cosmetic composition for preventing hair loss or hair growth.
  • the present invention also, in the manufacture of a cosmetic composition for preventing hair loss or hair growth, mixing at least one substance selected from the group consisting of apigenin, cumestrol, caffeine, ginseng extract and green tea extract and maple leaf extract Provided is the use of a mixture as a hair loss preventing agent or hair growth improving agent.
  • composition containing the maple leaf extract according to the present invention hair loss prevention or hair growth improvement effect is achieved by promoting the activity of the Wnt / ⁇ -catenin signaling system in tissues associated with hair loss, such as dermal papilla cells.
  • 1 is a graph showing the results of HPLC analysis of soybean leaf extract for each growth stage of soybean (bean leaf).
  • Figure 2 is a graph showing the HPLC analysis results of the maple leaf extract and soybean extract according to the present invention.
  • Figure 3 is a graph showing the degree of response according to the activity of the Wnt / ⁇ -catenin signaling system (Wnt / ⁇ -catenin signaling cascade) of the human dermal papilla cells treated with maple bean leaf extract or soybean extract according to the present invention.
  • Figure 4 is a graph showing the hair growth length of the human hair follicle organ treated with maple leaf extract or soybean extract according to the present invention.
  • the "foliage bean leaf” refers to the bean leaf color of the bean leaf yellow during the growth of the beans, such beans leaf during the growth stage of the beans 1) soybean pods and soybean turns yellow (time R7); From 2) with the leaves falling soybean pods and beans completely yellow (time R8); It means a bean leaf in.
  • the "foliage bean leaf” refers to a bean leaf in which a green or green bean leaf is in a yellow state (that is, a bean leaf in a partially yellow state) or a bean leaf in a completely yellow state.
  • the soybean leaves in the state where the soybean leaves are turned yellow are about 1/10 or more, preferably about 1/5 or more, more preferably about 1/3 or more, and particularly more preferably about 1/10 or more based on the total area of the soybean leaves. More than one half, most preferably about four fifths being yellow.
  • maple bean leaf extract may be extracted from the soybean leaves of R7 to R8 step of the growth of the following beans.
  • the growth stage of the beans is as follows.
  • VC stage cotyledon blooms, a word grows over it, and leaves
  • Step V1 A word is produced from the first outer leaf, resulting in three leaves
  • Stage V2 In the stage V1, one more word is created, resulting in three leaves
  • Phase V3 In the V2 phase, one more word is generated, resulting in three leaves
  • V4 stage In the V3 stage, one more word is created, creating three leaves
  • V5 stage An additional word in V4 stage creates 3 leaves
  • Step R4 Completed pod creation
  • Step R5 Soybeans inside the pod
  • Step R6 Green Beans Completed in the Pods
  • the activity change of the Wnt / ⁇ -catenin signaling system of the hair follicle stem cells according to the maple leaf extract treatment was measured.
  • the maple leaf extract when treated with maple leaf extract (Example 4) at a concentration of 10ppm or more, 150% or more Wnt / ⁇ -catenin luciferase reaction degree (that is, activity of the Wnt / ⁇ -catenin signaling system ), And the degree of reaction increased depending on the concentration of the maple leaf extract (Example 4). Therefore, the maple leaf extract was found to have a hair growth promoting effect by promoting the activity of the Wnt / ⁇ -catenin signaling system, a hair growth promoting signal of hair follicle stem cells (see Test Example 2).
  • the hair growth effect of the human hair follicle organ according to the maple leaf extract treatment was confirmed.
  • the maple leaf extract (Example 4) showed a hair growth effect equivalent to or greater than the positive control group in the concentration range of 1, 10 and 50ppm, especially hair length at 10ppm concentration Growth was the best. Therefore, it was confirmed that the maple leaf extract is effective in growing hair of human hair follicle organs (see Test Example 3).
  • the cell proliferation rate of human dermal papilla cells treated with 10 ppm maple leaf extract was the highest, indicating that they had the same level of cell proliferation effect as the human dermal papilla cells (positive control) treated with minoxidil. Confirmed.
  • any one selected from the group consisting of apigenin, cumestrol, caffeine, ginseng extract (Comparative Example 1) and green tea extract (Comparative Example 2) and 10ppm maple leaf extract (Example 4) Treatment of one mixture with human dermal papilla cells resulted in a significant increase in cell proliferation of human dermal papilla cells. Therefore, it was confirmed that there is a synergistic effect of further promoting the hair growth effect when the maple bean leaf extract and the substance are mixed and treated to human hair papilla cells (see Test Example 4).
  • Substances that promote hair growth through the regulation of the activity of the Wnt / ⁇ -catenin signaling system are not involved in promoting hair growth through the regulation of testosterone and / or blood circulation, thus inhibiting testosterone or promoting blood circulation.
  • the method will improve severe hair loss and gynecomastia that have not been resolved.
  • the present invention relates to a hair loss preventing or hair growth pharmaceutical composition, health functional food composition or cosmetic composition containing maple leaf extract as an active ingredient in one aspect, wherein the maple leaf extract is preferably a part or The whole may be extracted from the soybean leaves when turned yellow, and more preferably may be characterized in that extracted from the soybean leaves of R7 to R8 stage of the growth stage of the beans.
  • the present invention is to prevent hair loss comprising at least one selected from the group consisting of apigenin (apigenin), cumestrol (Coumestrol), caffeine, ginseng extract and green tea extract and maple leaf extract in a specific mixing ratio or It relates to a composition for improving hair growth.
  • the 'bean' is not limited in kind, for example, Seoritae ( Glycin max MERR), Seomoktae (Seomoktae, Rhynchosia Nolubilis ), Black soybean, Glycine max (L.) Merr., Blue bean, Glycime max MERR, Yellow bean, Glycime max MERR, Field bean, Vicia faba ), Kidney bean ( Phaseolus) vulgaris ), pinto bean, Phaseolus vulgaris L., small red bean, Vigna angularis ), small black bean, Phaseolus angularis WF WIGHT., bean sprouts (sprouting bean, Glycine max (L.) Merr.) and soybeans (soybean, Glycine max ) It is not limited to this.
  • Seoritae Glycin max MERR
  • Seomoktae Seomoktae, Rhynchosia Nolubilis
  • Black soybean Gly
  • the "foliage leaf extract” includes any material obtained by extracting the components of the maple leaf, regardless of the extraction method, extraction solvent, extracted component or form of the extract and extract the components It includes the material obtained by the extraction method including the process of treatment with heat, acid, base, enzyme, etc. in the process, and extracts the material obtained by extracting the components of the maple leaf and then processed by another method or It is a broad concept that includes all of the materials that can be obtained by treatment.
  • the processing or treatment may be to perform fermentation or enzyme treatment, such as maple leaf extract.
  • the maple bean leaf extract may be a fermentation product.
  • the "foliage bean leaf” may be in the form of an extract, or raw (bean) raw maple leaf, the pulverized product of the herbal medicine, dried product of the herbal medicine, dry ground product of the herbal medicine, fermented product of the maple bean leaf, but It is not limited.
  • the maple bean leaf used in the present specification is not limited to the acquisition method, may be grown and used or purchased commercially available, it may be used part or all of the ground or root portion of the herb. More specifically, one or more selected from the group consisting of leaves, stems, roots, and flowers of maple leaf herb may be used, and more specifically, flowers, leaves, and stems may be used.
  • the maple bean leaf is not necessarily produced through drying and is not limited as long as it is a raw material of a form suitable for extracting the active ingredient of the maple bean leaf.
  • the maple leaf extract may be one or more extracts selected from the group consisting of water, organic solvents and mixtures thereof.
  • the water comprises distilled or purified water
  • the organic solvent is one or more selected from the group consisting of C1 ⁇ C6 lower alcohol, acetone, ether, ethyl acetate, diethyl ether, ethyl methyl ketone and chloroform It includes, but is not limited to.
  • the alcohol may be methanol or ethanol.
  • improve or “alleviate” refers to the reduction or elimination of conditions, diseases, disorders or phenotypes, including abnormalities or symptoms, syndromes.
  • improving or alleviating hair loss refers to preventing, ameliorating or alleviating alopecia diseases by promoting the activity of the Wnt / ⁇ -catenin signaling system.
  • treatment refers to any activity in which the symptoms of alopecia disease improve or cure, and more specifically, to reverse the disease or condition to which the term applies, or one or more symptoms of the disease or condition. Means to mitigate, mitigate, inhibit, or prevent the progression of.
  • Maple bean leaf extract of the present invention may be characterized by containing a phyto-SERM (phyto-selective estrogen receptor modulator).
  • phyto-SERM is a combination of "phyto” meaning plant-derived and “selective estrogen receptor modulator” (SERM).
  • Selective estrogen receptor modulators refer to substances that bind to the estrogen receptor and act as estrogen agonists in some tissues and as estrogen antagonists in other tissues.
  • the composition containing the soybean leaf extract of the present invention acts as an antagonist to estrogen receptors in tissues such as the uterus and breast, which is highly likely to be carcinogenic, while lowering the risk of carcinogenesis such as uterine cancer and breast cancer, and more preferably the skin, preferably the scalp, more preferably.
  • Hair follicles are expected to contain phyto-SERM, which acts as an agent on human dermal papilla cells and is effective for promoting hair growth and preventing hair loss.
  • the maple leaf extract may be characterized in that it contains 1 to 60% by weight, preferably 5 to 50% by weight, more preferably 10 to 30% by weight based on the total weight of the composition have. If the content of the maple leaf extract is less than 1% by weight, it is difficult to expect hair growth promoting and hair loss prevention effects, and when the content of the content exceeds 60% by weight, the stability of the formulation is lowered, which affects the component stability of the extract. It is expected.
  • the composition may further comprise at least one selected from the group consisting of apigenin (apigenin), cumestrol (Coumestrol), caffeine, ginseng extract and green tea extract.
  • the composition contains a mixture of maple leaf extract and apigenin
  • the mixture is 1-10: 1-10, preferably 1-2: 1-2, of maple leaf extract and apigenin on a ppm concentration basis. More preferably, it may contain a mixing ratio of 2: 1.
  • the composition contains a mixture of maple leaf extract and cumestrol
  • the mixture is 1-10: 1-10, preferably 1-2: 1 ⁇ maple leaf extract and cumestrol on a ppm concentration basis. 2, More preferably, it is characterized by containing in a mixing ratio of 2: 1.
  • the composition contains a mixture of maple leaf extract and caffeine
  • the mixture is 1-10: 1-10, preferably 1-2: 1-2, more preferably, on a ppm concentration basis, maple leaf extract and caffeine It may be characterized by containing in a mixing ratio of 2: 1.
  • the composition contains a mixture of maple leaf extract and ginseng extract
  • the mixture is based on the ppm concentration
  • the composition contains a mixture of maple leaf extract and green tea extract
  • the mixture is based on the ppm concentration, 1 ⁇ 10: 1 ⁇ 10, preferably 1 ⁇ 2: 1 ⁇ 2, More preferably, it may contain a mixing ratio of 2: 1.
  • the mixture of the maple leaf extract and apigenin, the mixture of maple leaf extract and cumestrol, the mixture of maple leaf extract and caffeine, the mixture of maple leaf extract and ginseng extract, or the mixture of maple leaf extract and green tea extract are in the ppm concentration.
  • a mixture of apigenin, cumestrol, caffeine, ginseng extract and green tea extract may be mixed with a mixture ratio of the corresponding weight ratio (wt%) and maple bean leaf extract.
  • the soybean leaf extract may promote the activity of the Wnt / ⁇ -catenin signaling system, preferably promote the activity of the Wnt / ⁇ -catenin signaling system of dermal papilla cells, More preferably, it promotes the activity of the Wnt / ⁇ -catenin signaling system of human dermal papilla cells.
  • the bean leaf extract may be characterized by growing hair of the hair follicle organ.
  • the soybean leaf extract may be characterized by having the effect of promoting hair growth and / or hair loss symptoms by promoting the activity of the Wnt / ⁇ -catenin signaling system of the dermal papilla cells.
  • the pharmaceutical composition containing the maple leaf extract of the present invention is a preservative, stabilizer, hydrating or emulsifying accelerator, pharmaceutical adjuvants such as salts and / or buffers for the control of osmotic pressure and other therapeutically useful substances (carriers, excipients, diluents, etc.) ), And may be formulated in various oral or parenteral dosage forms according to conventional methods.
  • carrier is defined as a compound that facilitates the addition of a compound into a cell or tissue.
  • DMSO dimethyl sulfoxide
  • carrier facilitates the incorporation of many organic compounds into cells or tissues of an organism.
  • excipient is a substance that is added to make it easier to take medicine or to have a certain color and form when the amount of the main medicine is small in the process of preparation of tablets or pills, such as lactose or starch. do.
  • diot is defined as a compound that not only stabilizes the biologically active form of the compound of interest, but also is diluted in water to dissolve the compound. Salts dissolved in buffer solutions are used as diluents in the art. A commonly used buffer solution is phosphate buffered saline, because it mimics the salt state of human solutions. Because buffer salts can control the pH of a solution at low concentrations, buffer diluents rarely modify the biological activity of a compound.
  • compositions containing the Maple Leaf extract as used herein may be administered to a human patient as such or as a pharmaceutical composition mixed with other active ingredients as in combination therapy or with a suitable carrier or excipient.
  • Carriers, excipients and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose , Methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
  • the oral dosage forms include, for example, tablets, pills, hard and soft capsules, liquids, suspensions, emulsifiers, syrups, powders, powders, fine granules, granules, pellets, and the like, and these formulations include surfactants in addition to active ingredients. , Diluents such as lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and glycine, and glidants such as silica, talc, stearic acid and its magnesium or calcium salts and polyethylene glycols. .
  • Tablets may also contain binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
  • binders such as magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and polyvinylpyrrolidine, optionally starch, agar, alginic acid or its sodium salt
  • Pharmaceutical additives such as disintegrants, absorbents, colorants, flavors, and sweeteners.
  • the tablets can be prepared by conventional mixing, granulating or coating methods.
  • parenteral administration agent may be, for example, formulations such as injections, drops, ointments, lotions, gels, creams, sprays, suspensions, emulsions, suppositories, patches, and the like. It is not.
  • compositions according to an embodiment of the present invention may be administered orally, parenteral, rectal, topical, transdermal, intravenous, intramuscular, intraperitoneal, subcutaneous.
  • Pharmaceutical compositions according to one embodiment of the invention may be administered topically to the scalp, for example.
  • the pharmaceutically acceptable dose, ie dosage, of the active ingredient depends on the age, sex, and weight of the subject to be treated, the specific disease or pathology to be treated, the severity of the disease or pathology, the route of administration and the judgment of the prescriber Will be different. Dosage determination based on these factors is within the level of skill in the art.
  • the dosage is, for example, 1 to several times so as to be administered in an amount of 0.01 to 5000 mg, preferably 0.1 to 2000 mg, more preferably 0.5 to 500 mg, and most preferably 1 to 100 mg per kg of body weight per day. It can be administered in divided, but the dosage is not intended to limit the scope of the invention in any way.
  • Soybean leaf extract or maple soybean leaf extract of the present invention is a natural substance so there is no toxicity at all can be continuously used as a pharmaceutical.
  • compositions suitable for use in the present invention include compositions in which the active ingredients, including maple leaf extract, are contained in an amount effective to achieve their intended purpose. More specifically, a therapeutically effective amount means an amount of a compound effective to prolong the survival of the subject to be treated or to prevent, alleviate or alleviate the symptoms of a disease. Determination of a therapeutically effective amount is within the capabilities of those skilled in the art, in particular in terms of the detailed disclosure provided herein.
  • a therapeutically effective amount for maple leaf extract used in the methods of the invention, and compositions (compounds) containing the same as an active ingredient can be measured initially from cell culture assays. For example, dose can be calculated in an animal model to obtain a range of circulating concentrations that includes an IC 50 (half maximal inhibitory concentration) or EC 50 (half maximal effective concentration) determined in cell culture. Such information can be used to more accurately determine useful doses in humans.
  • Toxicity and therapeutic efficiency of the Maple Leaf Extract described herein, or compositions (compounds) containing it as an active ingredient are described, for example, LD 50 (fatal to 50% of the population), ED 50 ( 50 of the population).
  • IC 50 the dose with a therapeutic inhibitory effect on 50% of the population
  • the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio between LD 50 and ED 50 (or IC 50 ).
  • Compounds showing high therapeutic indices are preferred.
  • the data obtained from these cell culture assays can be used to estimate the range of doses used in humans.
  • the dosage or dosage of such compounds is preferably in the range of circulating concentrations including ED 50 (or IC 50 ) in the absence or little toxicity.
  • “Functional food” or “functional food” in the present invention means a food that improves the functionality of the general food by adding the maple bean leaf extract of the present invention to the general food.
  • Functionality can be roughly divided into physical properties and physiological functions.
  • the physical properties and physiological functions of general foods will be improved, and the present invention provides a food product of such an improved function as a comprehensive 'functional food.
  • Health functional food "or" functional food (health functional food) ".
  • health functional food refers to a food manufactured and processed using raw materials or ingredients having functional properties useful for the human body according to the Health Functional Food Act No. 10213, and nutrients for the structure and function of the human body. It is meant to be consumed for the purpose of regulating or obtaining a useful effect for health use such as physiological action.
  • the health functional food containing the maple bean leaf extract of the present invention may contain other ingredients and the like which can give a synergistic effect to the main effect within a range that does not impair the main effect of the present invention.
  • it may further include additives such as perfumes, pigments, fungicides, antioxidants, preservatives, moisturizers, thickeners, inorganic salts, emulsifiers and synthetic polymer materials to improve physical properties.
  • supplementary ingredients such as water soluble vitamins, oil soluble vitamins, polymer peptides, polymer polysaccharides and seaweed extract may be further included.
  • compositions of the present invention can be used in the form of additives for other foods.
  • the formulation of the health functional food containing the maple leaf extract of the present invention is not particularly limited, but is formulated in various forms such as tablets, granules, drinks, beverages, solutions, emulsions, viscous mixtures, tablets, powders, and the like. Can be.
  • the health functional food administration may be administered by a variety of methods, such as simple drinking, injection, spray or squeeze method.
  • the composition of the present invention may be formulated into a cosmetic formulation and used in various ways, such as hair cosmetics having a hair growth promoting effect.
  • the cosmetic composition containing the maple bean leaf extract of the present invention is not particularly limited in formulation, and may be appropriately selected as desired.
  • softening cream skin lotion and milk lotion
  • the composition of the present invention may include all components commonly used in cosmetics in addition to the extract, such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymer polysaccharides, sphingo It may comprise a component selected from the group consisting of lipid and seaweed extract.
  • the polymer peptide can be selected as long as it can be blended into cosmetics, but preferably collagen, hydrolyzed collagen, gelatin, elastin, hydrolyzed elastin, keratin and the like can be selected.
  • Polymeric peptides can be purified and obtained by conventional methods such as purification from microbial cultures, enzymatic methods or chemical synthesis methods, or can be purified and used from natural products such as dermis and pig silk such as pigs and cattle.
  • any one can be selected as long as it can be blended into cosmetics, but preferably hydroxyethyl cellulose, xanthan gum, sodium hyaluronate, chondroitin sulfate or a salt thereof (sodium salt, etc.) may be selected.
  • chondroitin sulfate or its salt, etc. can be normally purified from a mammal or fish.
  • sphingolipid any one can be selected as long as it can be blended into a cosmetic, but preferably ceramide, phytosphingosine, sphingosaccharide lipid and the like can be selected.
  • Sphingo lipids can usually be purified from mammals, fish, shellfish, yeasts or plants by conventional methods or obtained by chemical synthesis.
  • the cosmetic of the present invention may be blended with the above essential components, if necessary, with other ingredients normally blended into the cosmetic.
  • the compounding ingredients include fats and oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, ultraviolet absorbers, preservatives, fungicides, antioxidants, plant extracts, pH adjusters, alcohols, pigments, flavors, blood circulation accelerators , Cooling agent, limiting agent, purified water and the like can be used.
  • the compounding component which may be added other than this is not limited to this, Moreover, all said components can be mix
  • compositions included in the composition formulated in the cosmetic formulation of the present invention may include components commonly used in cosmetics in addition to the extract as an active ingredient, for example, stabilizers, solubilizers, vitamins, pigments and flavors and Such conventional adjuvants and carriers.
  • Example 4 the powder of the soybean leaf extract of Example V5 (Example 1), the soybean leaf extract of Example R2-3 (Example 2), the soybean leaf extract of Example R6 (Example 3), and the soybean leaf extract of Example R8 (Example 4) About 10.3 g of each was obtained.
  • Raw ginseng root was dried by daylight drying or hot air to prepare ginseng root drying material. About 3L of water was added to about 1 kg of the ginseng root dry material, and the mixture was extracted under reflux, filtered and concentrated under reduced pressure at 40 to 45 ° C. to obtain about 300 g of ginseng root extract.
  • Xinhua beans the same varieties as the beans used in the preparation of Examples 1-4, were washed with purified water, dried, and then semalized. About 100 g of the granulated soybean powder was added to 1 liter of an ethanol aqueous solution, and extracted at room temperature (25 ° C.) for about 24 hours, followed by filtration with a 300 mesh filter cloth. The filtrate was then concentrated to powder. Thus, about 10.3 g of a powder of soybean extract was obtained.
  • any one species selected from the group consisting of apigenin (Sigma, USA), cumestrol (Sigma, USA), caffeine (Sigma, USA), ginseng extract (Comparative Example 1) and green tea extract (Comparative Example 2) A mixture of a substance and maple leaf extract (Example 4) was prepared as in Examples 5 to 9 (see Table 2 below).
  • Test Example 1 Comparative Analysis of Components of Soybean Leaf Extract by Growth Stage
  • Example 1 The components of the soybean leaf extract (Examples 1 to 4) and the soybean extract (comparative example 3) for each growth stage were analyzed. Each of the extracts was dissolved in 70% ethanol to make a 10,000 ppm solution, followed by component analysis (Waters, 2996 PDA detector) using HPLC (Waters, 2695 model).
  • the stationary phase was Mightysil RP-18 GP 250-4.6 (5 ⁇ m) column of Kanto Chemical, and the mobile phase used the composition ratio shown in Table 1 below.
  • Test Example 2 of Hair Follicle Stem Cells Treated with Maple Bean Leaf Extract Wnt / ⁇ - Catenin Change in activity of signaling system
  • Wnt NIH3T3
  • luciferase a reporter protein capable of measuring activity changes of the Wnt / ⁇ -catenin signaling system
  • the maple leaf extract (Example 4) was treated in 1, 10, or 50 ppm of concentration in NIH3T3 (Wnt) cells incubated as described above and then cultured for about 24 hours (negative control: DMSO (Dimethyl Sulfoxide); positive control: Lithium chloride (LiCl) at 50 mM; Comparative example: Soybean Leaf Extract. Then, 100 ⁇ L of ONE-Glo reagent (Promega, Madison, WI, USA) was added to each well of the 96 well plate and reacted for 3 minutes. After the reaction, NIH3T3 was prepared using a luminometer Victor (PerkinElmer, Waltham, Massachusetts, USA).
  • Wnt / ⁇ -catenin luciferase response activity of the Wnt / ⁇ -catenin signaling system
  • Wnt / ⁇ -catenin luciferase assay was measured.
  • the maple leaf extract was found to have a hair growth promoting effect by promoting the activity of the Wnt / ⁇ -catenin signaling system, a hair growth promoting signal of hair follicle stem cells.
  • the maple leaf extract (Example 4) showed a hair growth effect equivalent to or greater than the positive control group in the concentration range of 1, 10 and 50ppm, especially hair length at 10ppm concentration Growth was the best.
  • the maple leaf extract is effective in growing hair of human hair follicle organs.
  • Test Example 4 human of maple leaf extract, and mixture containing same Breast milk Proliferative effect of cells
  • Human dermal papilla cells were seeded at 5000 cells / well in 96-well plates, incubated for about 24 hours under conditions of 5% CO 2 , 37 ° C, and then (i) maple leaf extract (Example 4: 1, 10 or 50 ppm), 0.1% DMSO (negative control), 50 ⁇ M minoxidil (positive control), respectively, to human dermal papilla cells, or (ii) apigenin, cumestrol, caffeine, ginseng extract (Comparative Example 1) or One test substance of green tea extract (Comparative Example 2) was mixed with maple leaf extract (Example 4: 10 ppm) at a concentration of 5 ppm, and treated with human dermal papilla cells, and cultured for about 72 hours, followed by MTT assay (3 Cell proliferation was confirmed by measuring the degree of cell proliferation by-(4,5-Dimethyl-2-thiazolyl) -2,5-diphenyl-2H-tetrazolium bromide tetrazolium reduction assay.
  • Example 4 sample Cell proliferation rate (%) Standard Deviation(%) 0.1% DMSO (Voice Control) 100.0 3.4 50 ⁇ M minoxidil (positive control) 112.4 9.0
  • Comparative Example 1 5 ppm ginseng extract 124.9 8.7 Comparative Example 2: 5 ppm green tea extract 106.5 5.1
  • human hair papilla cells treated with 1, 10 or 50 ppm maple leaf extract increased cell proliferation rate.
  • the cell proliferation rate of human dermal papilla cells treated with 10 ppm maple leaf extract (Example 4) was the highest, which was confirmed to have the same level of cell proliferation effect as human dermal papilla cells (positive control) treated with minoxidil. It was.
  • apigenin, cumestrol, caffeine, ginseng extract (Comparative Example 1) or green tea extract (Comparative Example 2) were treated to human dermal papilla cells at a concentration of 5 ppm, respectively, and the cell proliferation rate was increased.
  • the pharmaceutical, food and cosmetic composition containing the maple leaf extract of the present invention as an active ingredient may be commercialized (medicine, food, cosmetics) in various formulations of Formulation Examples 1 to 10, but is not limited thereto.
  • the present invention is applicable to various formulations and formulations containing an appropriate amount of maple leaf extract.
  • the following formulation also includes pharmaceutical, food and cosmetics containing a mixture of maple leaf extract and at least one substance selected from the group consisting of apigenin, cumestrol, caffeine, ginseng extract and green tea extract as an active ingredient. It may also be prepared in the form of a composition.
  • Maple bean leaf extract 80mg, vitamin E 9mg, vitamin C 9mg, palm oil 2mg, vegetable hardened oil 8mg, lead 4mg and lecithin 9mg were mixed and mixed according to a conventional method to prepare a soft capsule filling solution. 400 mg per capsule was filled to prepare a soft capsule.
  • a soft capsule sheet was prepared at a ratio of 66 parts by weight of gelatin, 24 parts by weight of glycerine, and 10 parts by weight of sorbitol solution and filled with the filler to prepare a soft capsule containing 400 mg of the composition according to the present invention.
  • Maple bean leaf extract 80mg, vitamin E 9mg, vitamin C 9mg, glucose 10g, citric acid 0.6g, and liquid oligosaccharide 25g was mixed, and then 300ml of purified water was added to each bottle to 200ml. After filling the bottle sterilized for 4 to 5 seconds at 130 °C to prepare a beverage.
  • the nutrient cosmetics containing the maple leaf extract of the present invention was prepared by mixing the components of Table 3 including an oil phase component and an aqueous phase component.
  • Massage cream containing the maple leaf extract of the present invention was prepared by mixing the components of Table 4 including the oil phase component and the water phase component.
  • the pack containing the maple leaf extract of the present invention was prepared by mixing the components of Table 5 including the oil phase component and the water phase component.
  • the hair tonic containing the maple leaf extract of the present invention was prepared by mixing the components of Table 6 including an oil phase component and an aqueous phase component.
  • the hair shampoo containing the maple leaf extract of the present invention was prepared by mixing the components of Table 7 including the oil phase component and the water phase component.
  • the hair conditioner containing the maple leaf extract of the present invention was prepared by mixing the components of Table 8 including the oil phase component and the water phase component.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Birds (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune et, plus précisément, une composition ayant un effet de prévention de la chute des cheveux ou d'amélioration de la croissance des cheveux grâce au fait qu'elle contient un extrait provenant de feuilles de soja ayant subi un jaunissement pendant la croissance du soja. Selon la présente invention, lorsque la composition contenant un extrait de feuilles de soja de couleur jaune est utilisée, on observe un effet de prévention de la chute des cheveux ou d'amélioration de la croissance des cheveux grâce à la stimulation de l'activité du système de signalisation Wnt/bêta-caténine dans un tissu, associé à la chute des cheveux, tel que des cellules de papille dermique.
PCT/KR2017/010817 2016-10-31 2017-09-28 Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune Ceased WO2018080039A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2016-0143111 2016-10-31
KR1020160143111A KR102635306B1 (ko) 2016-10-31 2016-10-31 단풍콩잎 추출물을 함유하는 탈모방지 또는 발모개선용 조성물

Publications (1)

Publication Number Publication Date
WO2018080039A1 true WO2018080039A1 (fr) 2018-05-03

Family

ID=62025143

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/010817 Ceased WO2018080039A1 (fr) 2016-10-31 2017-09-28 Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune

Country Status (3)

Country Link
KR (1) KR102635306B1 (fr)
TW (1) TW201817438A (fr)
WO (1) WO2018080039A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111297701A (zh) * 2020-03-13 2020-06-19 上海水分子婴童用品有限公司 泡沫洁肤巾及其制作工艺
CN113015513A (zh) * 2018-11-15 2021-06-22 株式会社爱茉莉太平洋 包含芹菜素的皮肤再生以及毛发生长促进用组合物

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102473645B1 (ko) 2020-08-28 2022-12-05 (주)부흥산업사 (2S,5R)-벤질 5-(t-부톡시카르보닐아미노)-2-메틸피페리딘-1-카르복실레이트의 제조방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080011970A (ko) * 2006-08-01 2008-02-11 (주)로다멘코스메딕스 푸에라리아 속 식물추출물을 함유하는 탈모방지 또는발모촉진용 조성물
US20120157478A1 (en) * 2010-12-21 2012-06-21 Dawson Jr Thomas Larry Hair Care Compositions and Methods to Improve Hair Appearance
KR20140033781A (ko) * 2012-09-10 2014-03-19 (주)아모레퍼시픽 콩잎 추출물을 포함하는 모발 및 두피 상태 개선용 조성물
KR20150030091A (ko) * 2013-09-11 2015-03-19 (주)아모레퍼시픽 인삼 다당체와 녹차 다당체를 함유하는 모발 또는 두피 상태 개선용 조성물
KR20150145704A (ko) * 2014-06-19 2015-12-30 (주)아모레퍼시픽 단풍콩잎 추출물을 포함하는 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102076001B1 (ko) 2012-09-10 2020-02-12 (주)아모레퍼시픽 콩잎 추출물을 포함하는 항염증용 조성물
KR102175249B1 (ko) 2013-09-11 2020-11-06 (주)아모레퍼시픽 인삼 추출물과 녹차 추출물을 함유하는 모발 또는 두피 상태 개선용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080011970A (ko) * 2006-08-01 2008-02-11 (주)로다멘코스메딕스 푸에라리아 속 식물추출물을 함유하는 탈모방지 또는발모촉진용 조성물
US20120157478A1 (en) * 2010-12-21 2012-06-21 Dawson Jr Thomas Larry Hair Care Compositions and Methods to Improve Hair Appearance
KR20140033781A (ko) * 2012-09-10 2014-03-19 (주)아모레퍼시픽 콩잎 추출물을 포함하는 모발 및 두피 상태 개선용 조성물
KR20150030091A (ko) * 2013-09-11 2015-03-19 (주)아모레퍼시픽 인삼 다당체와 녹차 다당체를 함유하는 모발 또는 두피 상태 개선용 조성물
KR20150145704A (ko) * 2014-06-19 2015-12-30 (주)아모레퍼시픽 단풍콩잎 추출물을 포함하는 조성물

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113015513A (zh) * 2018-11-15 2021-06-22 株式会社爱茉莉太平洋 包含芹菜素的皮肤再生以及毛发生长促进用组合物
CN113015513B (zh) * 2018-11-15 2024-03-05 株式会社爱茉莉太平洋 包含芹菜素的皮肤再生以及毛发生长促进用组合物
CN111297701A (zh) * 2020-03-13 2020-06-19 上海水分子婴童用品有限公司 泡沫洁肤巾及其制作工艺

Also Published As

Publication number Publication date
KR102635306B1 (ko) 2024-02-13
KR20180047227A (ko) 2018-05-10
TW201817438A (zh) 2018-05-16

Similar Documents

Publication Publication Date Title
KR102152750B1 (ko) 장미 추출물을 포함하는 조성물
KR20140115400A (ko) 붉나무 추출물을 유효성분으로 포함하는 탈모방지 및 발모촉진용 두피케어조성물
CN112770722B (zh) 小花风车子提取物在化妆品中的用途
WO2012169664A1 (fr) Agent dermique externe et aliment fonctionnel contenant un produit cultivé à partir de tissu de placenta de rose ou extrait de celui-ci
WO2021149880A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la croissance capillaire, comprenant, en tant que principe actif, un extrait mixte de concombre, d'aubergine et d'escargot
WO2016159567A2 (fr) Composition pour favoriser la croissance capillaire ou la régénération capillaire, et à effet anti-inflammatoire
WO2021215882A1 (fr) Composition pour prévenir la chute des cheveux ou favoriser la pousse des cheveux comprenant un extrait de péricarpe de camélia en tant que principe actif
WO2018080039A1 (fr) Composition destinée à prévenir la chute des cheveux ou à améliorer la croissance des cheveux, contenant un extrait de feuilles de soja de couleur jaune
KR20140012456A (ko) 아케비아 사포닌-디를 포함하는 피부 상태 개선용 조성물
WO2016117762A1 (fr) Composition contenant un extrait de groseille à maquereau ou du glutathion
WO2016056781A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait d'artemisia umbelliformis
WO2017119535A1 (fr) Composition anti-âge comprenant de la carnosine, peptide de soja, et extrait d'andrographis paniculata
WO2016056780A1 (fr) Composition pour prévenir la chute des cheveux ou stimuler la pousse des cheveux comprenant un extrait de scutellaria alpina
KR101467033B1 (ko) 대두 태좌 조직 배양물 또는 그 추출물을 함유하는 피부 외용제 조성물
WO2023022540A1 (fr) Composition de prévention de la perte de cheveux ou favorisant la pousse des cheveux comprenant un extrait de fleur de chardon-marie comme ingrédient actif
WO2015167240A1 (fr) Composition contenant un extrait de scutellaria alpina
WO2016003120A1 (fr) Composition de blanchiment comprenant un extrait de scutellaria alpina
KR102817967B1 (ko) 발효된 제주푸른콩의 추출물을 함유하는 탈모방지 또는 발모개선용 조성물
WO2015005700A1 (fr) Composition permettant de favoriser la repousse des cheveux et la croissance des cheveux
WO2014088258A1 (fr) Composition pour améliorer l'état de la peau comprenant de l'acide vératrique ou un sel acceptable de celui-ci en tant que principe actif
WO2016159642A1 (fr) Composition favorisant la pousse des cheveux et/ou la restauration de cheveux contenant de la psoralidine
WO2020218840A1 (fr) Composition pour inhiber la perte des cheveux ou favoriser la pousse des cheveux contenant un extrait de plante débarrassé de chlorophylle ou de pigment en tant que principe actif, et son procédé de production
WO2019164090A1 (fr) Composition contenant un extrait de symplocarpe fétide ou une fraction de celui-ci utilisé comme principe actif pour l'atténuation des rides
KR100561781B1 (ko) 방기 추출물을 유효성분으로 함유하는 피부 미백용 조성물
WO2025116202A1 (fr) Composition anti-âge contenant un extrait d'écorce de mandarine satsuma non mûre

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17865877

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17865877

Country of ref document: EP

Kind code of ref document: A1